



CME INSTITUTE

collective mindfulness

Tweetorial: Parkinson's Disease Psychosis: Current Therapies for Patients with PDP

April 18, 2023

[VIEW ON TWITTER](#)

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Faculty Affiliations

Michael Okun, MD

Department of Neurology
University of Florida College of Medicine
Gainesville, Florida

Emily Henderson, MBChB, MRCP, PhD

University of Bristol
Bristol, UK

Pamela Zeilman, APRN


Department of Neurology
University of Florida College of Medicine
Gainesville, Florida

Financial Disclosure

The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an "ineligible company" as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:

Dr. Okun has no financial disclosures.



CME INSTITUTE

collective mindfulness

Dr Henderson has received consulting fees from Abbvie and Bial; has received grant/research support from The Gatsby Foundation, National Institute of Health Research Health Technology Assessment, Elizabeth Blackwell Institute Health Data Strand, Engineering and Physical Sciences Research Council (EPSRC) Impact Acceleration Account, NIHR Research for Patient Benefit (RfPB) Programme, Alzheimer's UK Pump Priming Award, and British Geriatrics Society; has received honoraria for speaking/teaching from Kyowa Kirin, Abbvie, and Bial; has served on the advisory board for Abbvie; and received travel support from Bial.

Pamela Zeilman, MSN, has no financial disclosures.

Michael R. Page, PharmD, RPh
Independent Medical Director/Medical Writer
Plainsboro, New Jersey

Dr. Page is a consultant for BioCentric, Inc. and American Medical Communications, Inc.

None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.

Tweetorial References

Tweet #6

Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review [published correction appears in *Mov Disord*. 2019 May;34(5):765]. *Mov Disord*. 2019;34(2):180-198. <https://doi:10.1002/mds.27602>

Tweet #7

Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review [published correction appears in *Mov Disord*. 2019 May;34(5):765]. *Mov Disord*. 2019;34(2):180-198. <https://doi:10.1002/mds.27602>

Tweet #8

Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review [published correction appears in *Mov Disord*. 2019 May;34(5):765]. *Mov Disord*. 2019;34(2):180-198. <https://doi:10.1002/mds.27602>

Tweet #9

Isaacson SH, Citrome L. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions. *Expert Opinion on Drug Safety*. 2022 Jul 3;21(7):873-879. <https://doi.org/10.1080/14740338.2022.2069240>

Tweet #10

Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial [published correction appears in *Lancet*. 2014 Jul 5;384(9937):28]. *Lancet*. 2014;383(9916):533-540. [https://doi:10.1016/S0140-6736\(13\)62106-6](https://doi:10.1016/S0140-6736(13)62106-6)



CME INSTITUTE

collective mindfulness

Tweet #11

Pimavanserin PI. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b>. Accessed January 17, 2023.

Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial [published correction appears in Lancet. 2014 Jul 5;384(9937):28]. Lancet. 2014;383(9916):533-540. [https://doi:10.1016/S0140-6736\(13\)62106-6](https://doi:10.1016/S0140-6736(13)62106-6)

Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology. 2010;35(4):881-892. <https://doi:10.1038/npp.2009.176>

Tweet #12

Pimavanserin PI. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b>. Accessed January 17, 2023

Tweet #13

Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689-695. <https://doi:10.1136/jnnp.2003.029868>

Tweet #14

Fredericks D, Norton JC, Atchison C, Schoenhaus R, Pill MW. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden. Am J Manag Care. 2017;23(5 Suppl):S83-S92. <https://www.ajmc.com/view/parkinsons-disease-and-parkinsons-disease-psychosis-a-perspective-on-the-challenges-treatments-and-economic-burden-article>. Accessed January 17, 2023.

Tweet #15


Fredericks D, Norton JC, Atchison C, Schoenhaus R, Pill MW. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden. Am J Manag Care. 2017;23(5 Suppl):S83-S92. <https://www.ajmc.com/view/parkinsons-disease-and-parkinsons-disease-psychosis-a-perspective-on-the-challenges-treatments-and-economic-burden-article>. Accessed January 17, 2023.

Tweet #16

Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci. 2009;119(12):2196-2205. <https://doi:10.3109/00207450903222758>

Tweet #17

Fredericks D, Norton JC, Atchison C, Schoenhaus R, Pill MW. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden. Am J Manag Care. 2017;23(5 Suppl):S83-S92



CME INSTITUTE

collective mindfulness

Tweet #18

Nichols MJ, Hartlein JM, Eicken MG, Racette BA, Black KJ. A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease. *F1000Res*. 2013;2:150. Published 2013 Jul 9. <https://doi:10.12688/f1000research.2-150.v1>

Tweet #19

Martinez-Ramirez D, Okun MS, Jaffee MS. Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists. *Neurodegener Dis Manag*. 2016;6(4):319-330. <https://doi:10.2217/nmt-2016-0009>

Tweet #20

Parkinson's Foundation. Hallucinations/Delusions. <https://www.parkinson.org/understanding-parkinsons/non-movement-symptoms/hallucinations-delusions>. Accessed January 17, 2023.



CME INSTITUTE

collective mindfulness

Glossary

5-HT2A	5-hydroxy-tryptamine
AE	Adverse Event
ALT	Alanine Transaminase
CGI	Clinical Global Impression Scale
KINECT-3	NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
VMAT2	Vesicular Monoamine Transporter 2